Abstract

SummaryNewly emerging or re-emerging viral infections continue to cause significant morbidity and mortality every year worldwide, resulting in serious effects on both health and the global economy. Despite significant drug discovery research against dengue viruses (DENVs) and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), no fully effective and specific drugs directed against these viruses have been discovered. Here, we examined the anti-DENV activity of tubercidin derivatives from a compound library from Hokkaido University and demonstrated that 5-hydroxymethyltubercidin (HMTU, HUP1108) possessed both potent anti-flavivirus and anti-coronavirus activities at submicromolar levels without significant cytotoxicity. Furthermore, HMTU inhibited viral RNA replication and specifically inhibited replication at the late stages of the SARS-CoV-2 infection process. Finally, we demonstrated that HMTU 5′-triphosphate inhibited RNA extension catalyzed by the viral RNA-dependent RNA polymerase. Our findings suggest that HMTU has the potential of serving as a lead compound for the development of a broad spectrum of antiviral agents, including SARS-CoV-2.

Highlights

  • Emerging and re-emerging viral infectious diseases have been found to have a significant negative impact on global human health and global economies

  • Despite significant drug discovery research against dengue viruses (DENVs) and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), no fully effective and specific drugs directed against these viruses have been discovered

  • Our findings suggest that HMTU has the potential of serving as a lead compound for the development of a broad spectrum of antiviral agents, including SARS-CoV-2

Read more

Summary

Introduction

Emerging and re-emerging viral infectious diseases have been found to have a significant negative impact on global human health and global economies. Despite significant progress in medical treatment and the pharmacological sciences, these viral infections continue to cause millions of cases of disease and deaths worldwide annually. Since the first reported case in December 2019, severe acute respiratory syndrome coronavirus-2 (SARSCoV-2) has rapidly spread from person to person, and SARS-CoV-2 infection is pandemic. The severe pneumonia-like disease caused by SARS-CoV-2, designated as coronavirus disease 2019 (COVID-19), has been linked to more than million confirmed cases and 4.1 million deaths in countries/regions [https://coronavirus.jhu.edu/map.html]. SARS-CoV-2 is a member of the Betacoronavirus genus of the family Coronaviridae, which consists of several types of human coronaviruses (HCoVs), including HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU1, SARS-CoV, and Middle East respiratory syndrome coronavirus (MERS-CoV). There are as yet no fully effective specific drugs directed against SARS-CoV-2, and as such, effective therapeutic agents and vaccines against this virus are urgently needed

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call